公开(公告)号：US09920115B2

公开(公告)日：2018-03-20

申请号：US15704513

申请日：2017-09-14

Applicant: Harpoon Therapeutics, Inc.

Inventor： Robert B. Dubridge ,  Bryan D. Lemon ,  Richard J. Austin ,  Luke Evnin ,  Jeanmarie Guenot

IPC: A61K39/395 ,  C07K16/18 ,  C07K16/00 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/005 ,  C07K16/2809 ,  C07K16/2887 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/92 ,  C07K2317/94

Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.

公开(公告)号：US10815311B2

公开(公告)日：2020-10-27

申请号：US16583070

申请日：2019-09-25

Applicant: Harpoon Therapeutics, Inc.

Inventor： Holger Wesche ,  Richard J. Austin

IPC: C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  C07K16/46 ,  A61K39/00

Abstract: Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein). Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such DLL3 binding proteins, DLL3 targeting trispecific proteins. Also disclosed are methods of using the disclosed DLL3 binding proteins, DLL3 targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

公开(公告)号：US20190135930A1

公开(公告)日：2019-05-09

申请号：US16159545

申请日：2018-10-12

Applicant: HARPOON THERAPEUTICS, INC.

Inventor： Holger Wesche ,  Bryan D. Lemon ,  Richard J. Austin

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61P35/04 ,  A61P35/02

Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.

公开(公告)号：US11807692B2

公开(公告)日：2023-11-07

申请号：US16999773

申请日：2020-08-21

Applicant: Harpoon Therapeutics, Inc.

Inventor： Holger Wesche ,  Richard J. Austin

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61P35/00 ,  C07K16/46 ,  C07K16/18 ,  A61K39/00

CPC classification number: C07K16/468 ,  C07K16/18 ,  C07K16/2809 ,  C07K16/30 ,  A61K39/395 ,  A61K2039/505 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein). Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such DLL3 binding proteins, DLL3 targeting trispecific proteins. Also disclosed are methods of using the disclosed DLL3 binding proteins, DLL3 targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

公开(公告)号：US11623958B2

公开(公告)日：2023-04-11

申请号：US16773806

申请日：2020-01-27

Applicant: Harpoon Therapeutics, Inc.

Inventor： Robert B. Dubridge ,  Pui Seto ,  Richard J. Austin ,  Luke Evnin ,  Jeanmarie Guenot ,  Bryan Lemon

IPC: C07K16/28 ,  C07K16/18

Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.

公开(公告)号：US11180563B2

公开(公告)日：2021-11-23

申请号：US17180435

申请日：2021-02-19

Applicant: Harpoon Therapeutics, Inc.

Inventor： Holger Wesche ,  Richard J. Austin

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/18 ,  A61P35/02

Abstract: Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins. Also disclosed are methods of using the disclosed FLT3 binding proteins in the prevention, and/or treatment of diseases, conditions and disorders.

公开(公告)号：US11136403B2

公开(公告)日：2021-10-05

申请号：US16159554

申请日：2018-10-12

Applicant: HARPOON THERAPEUTICS, INC.

Inventor： Holger Wesche ,  Bryan D. Lemon ,  Richard J. Austin

IPC: A61K39/00 ,  C07K16/28 ,  A61P35/00 ,  C07K16/18

Abstract: Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

公开(公告)号：US11976125B2

公开(公告)日：2024-05-07

申请号：US17150272

申请日：2021-01-15

Applicant: Harpoon Therapeutics, Inc.

Inventor： Holger Wesche ,  Bryan D. Lemon ,  Richard J. Austin

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07K16/18 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K47/6849 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07K16/18 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2317/94

Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.

公开(公告)号：US10927180B2

公开(公告)日：2021-02-23

申请号：US16159545

申请日：2018-10-12

Applicant: HARPOON THERAPEUTICS, INC.

Inventor： Holger Wesche ,  Bryan D. Lemon ,  Richard J. Austin

IPC: C07K16/28 ,  A61P35/00 ,  A61P35/04 ,  A61P35/02 ,  A61K47/68 ,  C07K16/18 ,  A61K39/00

Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.

公开(公告)号：US10730954B2

公开(公告)日：2020-08-04

申请号：US15977988

申请日：2018-05-11

Applicant: Harpoon Therapeutics, Inc.

Inventor： Holger Wesche ,  Bryan D. Lemon ,  Richard J. Austin ,  Robert B. Dubridge

IPC: C07K16/18 ,  C07K16/30 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.